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Letter to the Editor
Dear Sir:
Shortening the interval between hospital arrival and thrombo-
lytic treatment is critical to improve the efficacy of the treat-
ment because of its time-sensitive effect.1 Decision-making by 
patients or their families is an essential step during the process 
of thrombolytic treatment. In an emergency situation, decision-
making by patients or their families relies mostly on the physi-
cian’s explanation concerning the benefits and risks of thrombo-
lytic treatment. In this regard, a physician’s concise, standard-
ized, and easily understandable explanation of the thrombolytic 
treatment is important for the process of decision-making and 
for obtaining informed consent from patients or their family. We 
investigated how a protocol using decision-making support 
(DMS) for patients and their families could reduce door-to-nee-
dle time in acute stroke. 
We have previously shown that quality improvement activity 
using a computerized physician order entry could reduce time 
from hospital arrival to evaluations and intravenous (IV) tissue 
plasminogen activator (tPA).2-4 While performing continuous 
quality improvement activity to further improve the process, we 
have found that the most common reason of treatment delay 
was waiting informed consent.5 Therefore, we developed a proto-
col for DMS using standardized scrip and visual decision aid. The 
standardized script was developed for physicians who are respon-
sible for providing explanations regarding thrombolysis treatment 
and then obtaining informed consent from patients or their fami-
lies. The visual decision aid (http://stroke.ucla.edu/workfiles/VDA-
for-TPA.pdf) was used by physicians to help explain the benefits 
and risks of IV tPA treatment to candidates for this treatment. 
This protocol was implemented from January 2010.
All consecutive patients who visited the emergency depart-
ment and were treated with IV tPA within the 3-hour time win-
dow were included in this study. The effect of DMS was investi-
gated by comparing the door-to-needle time before (the pre-
DMS group, January 2007–December 2009) and after (post-DMS 
group, January 2010–December 2012) the implementation of 
the DMS protocol. Demographic factors and time intervals were 
compared using the Mann–Whitney U test and the chi-square 
test. The possible reasons for delay were identified if the door-
to-needle time was longer than 40 minutes. To determine fac-
tors associated with a door-to-needle time >40 minutes, multi-
variable logistic regression analysis was performed. Age, sex, and 
variables with P<0.1 in the univariable analyses were entered 
for multivariable analysis. Statistical significance was set at 
P<0.05. SPSS for Windows (version 17.0, SPSS Inc., Chicago, IL, 
USA) was used for statistical analysis. 
Total of 2,172 and 2,078 patients with cerebral infarction were 
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admitted to the neurology department during the 3-year pre-
DMS and 3-year post-DMS periods, respectively. Of them, 229 
patients who were treated with IV tPA (the pre-DMS group 111 
[5.1%], the post-DMS group 118 [5.7%], P=0.412) were includ-
ed in this study. When comparing with the pre-DMS group, the 
post-DMS group more frequently had diabetes mellitus (36.4% 
vs. 21.6%, P=0.014) and less frequently had a history of previ-
ous cerebral infarction (9.3% vs. 18.9%, P=0.036). Baseline Na-
tional Institute of Health Stroke Scale score was lower in the 
post-DMS group (median [interquartile range]: 13 [8-17] vs. 15 
[9-20], P=0.013). Other demographic characteristics were not 
different between the groups. The median door-to-needle time 
was significantly reduced after the implementation of the DMS 
protocol (from 46 minutes [interquartile range 38-58] to 40 
minutes [interquartile range 34-47], P=0.001). The proportion of 
patients who received IV tPA treatment within 40 minutes was 
greater in the post-DMS group (64/118 [54.2%]) than in the pre-
DMS group (40/111 [36.0%], P=0.006). The reduction of door-
to-needle time was observed soon after the implementation of 
the DMS protocol and was sustained for the 3-year follow-up 
period (Figure 1). Multivariate analysis showed that the imple-
mentation of the DMS protocol was independently associated 
with a door-to-needle time ≤40 minutes (adjusted odds ratio 
2.13, 95% confidence interval 1.23-3.67). In the pre-DMS group, 
waiting for informed consent due to the indecision of family 
members was the most common reason for delay (23/71, 32.4%). 
After the implementation of DMS protocol, the delay due to 
waiting for informed consent was substantially reduced (8/54 
[14.8%], P=0.024).
In this study, we demonstrated that door-to-needle time was 
significantly reduced in the post-DMS group that used a stan-
dardized script and visual decision aid for tPA treatment. Al-
though many quality improvement initiatives and programs have 
been implemented to reduce any delay in reperfusion therapy in 
stroke,3-9 there has been little concern regarding the decision-
making process of patients or their family. We interviewed neu-
rology residents who were primarily responsible for obtaining in-
formed consent. We recognized that the explanations on the 
benefits and risks of IV tPA differed among residents, and might 
also be biased. Therefore, we provided standardized scripts con-
taining key messages to explain. This script was helpful for stan-
dardizing the explanations, preventing potential bias, and short-
ening the time taken for providing the explanation and obtaining 
informed consent. We also used a visual decision aid that shows 
how many patients benefitted or experienced adverse conse-
quences when they are treated with IV tPA within 3 hours after 
symptom onset. Patients and their family often have difficulties 
in understanding medical terms and the benefits and risks of re-
perfusion treatment despite the physician’s explanations. The vi-
sual decision aid showing the benefits and risks of tPA treatment 
as a simple cartoon was helpful for our study population. Recent 
pooled analysis revealed that decision aids significantly improved 
people’s knowledge regarding options, and reduced their deci-
sional conflict,10 which supports our findings.
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Figure 1. Door-to-needle time for intravenous tissue-type plasminogen activator before and after implementation of decision making support proto-
col. Door-to-needle time was reduced soon after the implementation of the decision-making support (DMS) protocol and maintained for the 3-year 
follow-up period.
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To reduce delay in thrombolysis treatment, efforts to improve 
the process should be multi-directional. Although the 6-minute 
reduction of door-to-needle time, by improving the patient’s or 
family’s decision-making, may not seem great, it was achieved by 
using a simple protocol that could be easily implemented in any 
hospital setting. In addition, the effect of the standardized script 
and visual decision aid seems to be immediate and sustainable. 
Therefore, more widespread implementation of this approach is 
warranted because it is simple and can be easily implemented. 
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